在早期非小细胞肺癌的立体性废除性放射治疗后的生存分析:单一机构队列研究
Kamila Resova1,2, Lukas Knybel3,4, Tereza Parackova1,2
1Dept. of Oncology, University Hospital Ostrava, 17. listopadu 1790, 708 52, Ostrava, Czech Republic.
Radiation oncology (London, England)
|April 18, 2024
概括
对于医疗上不可操作的早期非小细胞肺癌 (ES-NSCLC) 的类立体除性放射治疗 (SABR) 是有效的. 男性性别和高并发症指数预测3年后的整体存活率 (OS) 较差.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 胸部外科手术 胸部外科手术
背景情况:
- 立体除性放射治疗 (SABR) 是医疗上不可操作的早期非小细胞肺癌 (ES-NSCLC) 的标准.
- 确定从SABR中获益最多的患者至关重要.
- 这项研究旨在确定ES-NSCLC患者SABR.治疗的早期死亡的预后因素.
研究的目的:
- 分析SABR.治疗的医疗不可操作的早期非小细胞肺癌 (ES-NSCLC) 患者早期死亡的预后因素.
- 评估各种临床和剂量测量因素与整体存活时间 (OS) 之间的关联.
主要方法:
- 连续172名医学上不可操作的ES-NSCLC患者的回顾性分析 (2018-2020年) 用SABR治疗.
- 考克斯的比例危险模型用于单变量和多变量分析.
- 分析的变量包括FEV1,组织学,年龄,T阶段,瘤部位,性别,PET,生物有效剂量 (BED) 和年龄调整的查尔森并发症指数 (AACCI).
主要成果:
- 平均整体存活时间 (OS) 为35.3个月.
- 多变量分析确定男性性别 (HR 1.51) 和AACCI>5 (HR 1.56) 作为OS的显著负预后因素.
- AACCI>5对OS的负面影响在3年后变得显著,在1年没有差异.
结论:
- 精确图像指导的SABR是一种可行的治疗方法,用于医疗不可操作的ES-NSCLC患者,具有合理的性能状态.
- 在这个现实世界的队列中,早期死亡率很罕见.
- 总体存活率高于预期,仅仅是最好的支持性护理.
更多相关视频
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
14.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
相关概念视频
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
01:20Actuarial Approach
77
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
77
01:20Comparing the Survival Analysis of Two or More Groups
179
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
179